53P Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with ≥50% expression of programmed cell death-ligand 1 (PD-L1): A multi... von Perea, J., Gómez, E., Escrivá, C., Pellicer, A.V., Rodriguez, P. Llor, Iranzo, J., Vidal, O.J. Juan, Sanchez, J. García, Montagud, G. Suay, Míco, A. Ferrero, Diaz, I. Linares, Sepúlveda, N. Gómez, Hernández, E. Soria, Gallego, J. Esteve, Carrasco, C., Gaudens, P. Capdevila

Volltext

56P Continuation treatment with immunotherapy beyond two years in patients with metastasic non-small cell lung cancer: Retrospective analysis of optimal duration treatment von Pellicer Boigues, A.V., Garde Noguera, J., Garcia Sanchez, J., Piera, N., Fenollosa Sanz, T., Llor Rodriguez, P., Iranzo Barreira, J., Riquelme Cabrera, P., Fernandez Murga Chavanne, M.L., Llombart Cussac, A.

Volltext

The Permselectivity of Membrane Systems with an Inhomogeneous Distribution of Fixed Charge Groups von Sokirko, Artjom V., Manzanares, José A., Pellicer, Julio

Volltext